220 related articles for article (PubMed ID: 9652766)
1. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J
Br J Cancer; 1998 May; 77(9):1487-91. PubMed ID: 9652766
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.
Latreille J; Stewart D; Laberge F; Hoskins P; Rusthoven J; McMurtrie E; Warr D; Yelle L; Walde D; Shepherd F
Support Care Cancer; 1995 Sep; 3(5):307-12. PubMed ID: 8520877
[TBL] [Abstract][Full Text] [Related]
3. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
4. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
6. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis.
Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Hojo F; Matsumoto T; Ohmatsu H; Yokozaki M; Kodama T
Jpn J Clin Oncol; 1996 Jun; 26(3):164-8. PubMed ID: 8656557
[TBL] [Abstract][Full Text] [Related]
7. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
Campos D; Pereira JR; Reinhardt RR; Carracedo C; Poli S; Vogel C; Martinez-Cedillo J; Erazo A; Wittreich J; Eriksson LO; Carides AD; Gertz BJ
J Clin Oncol; 2001 Mar; 19(6):1759-67. PubMed ID: 11251007
[TBL] [Abstract][Full Text] [Related]
8. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
9. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
10. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
Hesketh PJ; Roman A; Hesketh AM; Perez EA; Edelman M; Gandara DR
Support Care Cancer; 2000 Jan; 8(1):46-8. PubMed ID: 10650897
[TBL] [Abstract][Full Text] [Related]
11. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Morrow GR; Hickok JT; Rosenthal SN
Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
[TBL] [Abstract][Full Text] [Related]
12. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.
Heron JF; Goedhals L; Jordaan JP; Cunningham J; Cedar E
Ann Oncol; 1994 Sep; 5(7):579-4. PubMed ID: 7993831
[TBL] [Abstract][Full Text] [Related]
13. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.
Latreille J; Pater J; Johnston D; Laberge F; Stewart D; Rusthoven J; Hoskins P; Findlay B; McMurtrie E; Yelle L; Williams C; Walde D; Ernst S; Dhaliwal H; Warr D; Shepherd F; Mee D; Nishimura L; Osoba D; Zee B
J Clin Oncol; 1998 Mar; 16(3):1174-8. PubMed ID: 9508205
[TBL] [Abstract][Full Text] [Related]
14. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study.
Goedhals L; Heron JF; Kleisbauer JP; Pagani O; Sessa C
Ann Oncol; 1998 Jun; 9(6):661-6. PubMed ID: 9681082
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
16. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
17. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced emesis in the cat: effect of granisetron and dexamethasone.
Rudd JA; Tse JY; Wai MK
Eur J Pharmacol; 2000 Mar; 391(1-2):145-50. PubMed ID: 10720646
[TBL] [Abstract][Full Text] [Related]
19. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research.
Ann Oncol; 1995 Oct; 6(8):805-10. PubMed ID: 8589019
[TBL] [Abstract][Full Text] [Related]
20. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
